Related Experiment Video
Updated: Jul 16, 2026
Cell-based Assay Protocol for the Prognostic Prediction of Idiopathic Scoliosis Using Cellular Dielectric Spectroscopy
Published on: October 16, 2013
Gelsolin as a predictor marker for late-onset fetal growth restriction and adverse neonatal outcomes: A prospective
Gizem Aktemur1, Betül Tokgöz Çakır1, Gülşan Karabay1
1Department of Obstetrics and Gynecology, Division of Perinatology, Ankara Etlik City Hospital, Ankara, Turkey.
Objective:
Fetal growth restriction (FGR) is a major cause of neonatal morbidity and mortality. This study investigates the potential of gelsolin (GSN), an actin-regulating protein with anti-inflammatory properties, as a biomarker for early late-onset FGR detection and predicting adverse neonatal outcomes.
Methods:
In a prospective, cross-sectional study conducted at Ankara Etlik City Hospital, maternal blood samples were collected from 1016 pregnant individuals at 11-14 weeks gestation. After exclusion criteria were applied, 64 late-onset FGR patients and 72 controls were analyzed. Serum GSN levels were assessed via ELISA, and statistical analyses were conducted to determine correlations with late-onset FGR and neonatal outcomes. ROC curve analysis was performed to identify optimal GSN cut-off values.
Results:
GSN levels were significantly higher in the late-onset FGR group compared to controls (4.396 ± 3.39 ng/mL vs. 0.925 ± 0.43 ng/mL; p < 0.001). A GSN cut-off of 0.999 ng/mL predicted late-onset FGR with a sensitivity of 78.1 % and specificity of 66.7 % (AUC = 0.852). A higher GSN cut-off of 3.863 ng/mL predicted adverse neonatal outcomes within the late-onset FGR group with a sensitivity of 63.4 % and specificity of 60.9 % (AUC = 0.703).
Conclusion:
Elevated first trimester GSN levels are associated with late-onset FGR and adverse neonatal outcomes. Monitoring GSN could serve as an early, non-invasive screening tool for high-risk pregnancies, facilitating timely intervention and specialized care. This study provides evidence supporting GSN as a promising biomarker in late-onset FGR prediction, contributing to the improvement of maternal-fetal healthcare.
